Clinical Trial Update: RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating RC48 plus tislelizumab, low-dose capecitabine, and celecoxib for HER2-positive metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Celecoxib (Celecoxib)
• RC48 (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN